International Journal of Hematology

, Volume 99, Issue 4, pp 413–417 | Cite as

Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients

  • Anil Kumar Tripathi
  • Ayush Shukla
  • Sanjay Mishra
  • Yogendra Singh Yadav
  • Deependra Kumar Yadav
Original Article


Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterised by isolated thrombocytopenia (peripheral blood platelet count <100 × 109/L) in the absence of other causes or disorders that may be associated with thrombocytopenia. The upfront treatment in newly diagnosed ITP patients is steroids; however, about one-third patients do not respond, and require other treatment, including IVIg, anti-D, or splenectomy. Previous studies have shown decreased platelet production in some ITP patients, aside from the evidence of enhanced platelet destruction. Thrombopoietin receptor agonists (TPO-RA), such as eltrombopag have been shown to provide good response in steroid non-responsive chronic ITP patients. We have studied response to eltrombopag in 25 newly diagnosed steroid non-responsive ITP patients; 80 % patients showed response at the end of 1 month, and 76 % sustained response at the end of 3 months. The platelet count rose from a mean value of 17.5 ± 3.6–152.5 ± 107.9 × 109/L at the end of 1 month. Our results suggest a possible role of eltrombopag in newly diagnosed steroid non-responsive ITP patients. However, our study is limited in that it is a single-centre study, with a small sample size, and lacks a long-term safety profile. Our findings highlight the potential value of a larger prospective study on the upfront use of TPO-RA in patients of ITP.


Primary ITP ITP TPO-RA Eltrombopag 


  1. 1.
    Rodeghiero F, Roberto S, Terry GM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.PubMedCrossRefGoogle Scholar
  2. 2.
    Houwerzijl EJ, Blom NR, Van der Want JJL, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103:500–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Stasi R, Provan D. Management of immune thrombocytopenia in adults. Mayo Clin Proc. 2004;79:504–22.PubMedCrossRefGoogle Scholar
  4. 4.
    Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–47.PubMedCrossRefGoogle Scholar
  5. 5.
    McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol. 2007;44(4 Suppl 5):S3–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Olsson B, Anderson PO, Jemas M, et al. T cell mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Chow L, Aslam R, Speck ER, et al. A murine model of severe thrombocytopenia is induced by antibody and CD 8+ T cell mediated responses that are differentially sensitive to therapy. Blood. 2010;115(6):1247–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Sakakura M, Wada H, Tawara I, et al. Reduced CD4+ CD25− T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res. 2007;120(2):187–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Ballem PJ, Segal GM, Stratton JR, et al. Mechanism of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80(1):33–40.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomized, phase 3 study. Lancet. 2011;377(9763):393–402.PubMedCrossRefGoogle Scholar
  11. 11.
    Saleh MN, Bussel JB, Cheng G, et al. EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. NEJM. 2010;363(20):1889–961.PubMedCrossRefGoogle Scholar
  13. 13.
    Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009;27(2):424–30.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Tripathi A, Mishra S, Yadav D et al. Megakaryocyte morphology and its impact in predicting response to steroid in immune thrombocytopenia. Platelets 2013 (in press).Google Scholar

Copyright information

© The Japanese Society of Hematology 2014

Authors and Affiliations

  • Anil Kumar Tripathi
    • 1
  • Ayush Shukla
    • 1
  • Sanjay Mishra
    • 1
  • Yogendra Singh Yadav
    • 1
  • Deependra Kumar Yadav
    • 1
  1. 1.Department of Clinical Hematology and Medical OncologyKing George’s Medical UniversityLucknowIndia

Personalised recommendations